Global Trends in PD-1/PD-L1 Inhibitor Patents: A Comprehensive Analysis of Patent Landscapes and Therapeutic Innovations

• Global patent filings for PD-1/PD-L1 inhibitors have grown exponentially, with China emerging as a major contributor. • Combination therapies and novel modalities (e.g., bispecific antibodies) are driving recent patent activity. • The United States and China lead in patent filings, but Europe shows significant activity in specific therapeutic areas. • Strategic patent management is crucial for navigating the competitive landscape of PD-1/PD-L1 inhibitors.